跳转至内容
Merck

GF54212914

foil, not light tested, 100x100mm, thickness 0.025mm, as rolled, 99%

别名:

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
La
CAS号:
分子量:
138.91
MDL號碼:
分類程式碼代碼:
12141607
PubChem物質ID:
NACRES:
NA.23

化驗

99%

形狀

foil

製造商/商標名

Goodfellow 542-129-14

電阻係數

54 μΩ-cm

尺寸 × 厚度

100x100 mm × 0.025 mm

bp

3464 °C (lit.)

mp

920 °C (lit.)

密度

6.19 g/mL at 25 °C (lit.)

SMILES 字串

[La]

InChI

1S/La

InChI 密鑰

FZLIPJUXYLNCLC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

For updated SDS information please visit www.goodfellow.com.

法律資訊

Product of Goodfellow

儲存類別代碼

4.3 - Hazardous materials which set free flammable gases upon contact with water

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
Declan de Freitas et al.
Seminars in dialysis, 20(4), 325-328 (2007-07-20)
Hyperphosphatemia is associated with increased morbidity and mortality in dialysis patients. Oral phosphate binders are necessary to control serum phosphate in patients eating a normal diet and undergoing peritoneal dialysis or thrice weekly hemodialysis. Until recently, none of the available
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门